TC |
Stat |
Stk |
Ins |
Fil |
+d |
+w |
+m |
+q |
+h |
+y |
avg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| P | %ret | 3 | 1 | 3 | 4 | 7 | 3 | -16 | 17 | -3 | 2 |
| P | %wins | 100 | 100 | 33 | 0 | 33 | 50 | 53 |
Filing Date |
T Date |
Ticker |
Issuer | Inc | Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
8/12/16 16:37 | 8/11/16 | VRX | Valeant Pharmaceuticals International, Inc. | A8 | Health | Drug | Pharmaceutical Preparations | Karabelas Argeris N | NJ | D | P | 99 | 24.65 | 33 | 4 | 24 | 21 | D | -77 | -90 | -71 | -2 | 22 | 7 | 16 | 9 | 7 | 17 | 15 | -36 | -40 | ||
2/25/15 18:19 | 2/23/15 | ITEK | Inotek Pharmaceuticals Corp | DE | Health | Drug | Pharmaceutical Preparations | Karabelas Argeris N | NJ | DT | P.d | 3,623 | 6.00 | 7 | 604 | 36 | 2,277 | I | -1 | 1 | 0 | -3 | -3 | 107 | 18 | ||||||||
11/14/06 16:32 | 11/10/06 | HGSI | Human Genome Sciences Inc | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Karabelas Argeris N | MD | D | P | 152 | 12.15 | 33 | 13 | New | 13 | D | 11 | 33 | 17 | 27 | 2 | -1 | -7 | -3 | 4 | 3 | -2 | -9 | -17 | -23 |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |